Loading filters...
Publications per Year (4238 total)
16
1990
22
·
26
·
42
·
34
·
56
1995
43
·
36
·
49
·
54
·
31
2000
51
·
47
·
59
·
66
·
115
2005
142
·
108
·
126
·
118
·
126
2010
126
·
141
·
148
·
144
·
154
2015
156
·
209
·
193
·
198
·
205
2020
246
·
198
·
199
·
195
·
231
2025
128
·
Loaded
Click to load
50 / 4238 papers loaded(scroll for more)
202650 papers
ImmunotherapyAdvanced/Metastatic (IV)2026
Real-world outcomes of pembrolizumab-chemotherapy combination in metastatic non-small cell lung cancer by age and sex: A national population-based study.
Yiu CH et al. Lung Cancer. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Vo-Quang E et al. Eur J Cancer. 2026
EGFR mutantAll Stages2026
Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer.
Higashiyama RI et al. Br J Cancer. 2026
EGFR mutantAll Stages2026
Prevention and management of amivantamab-induced dermatologic toxicities: a European expert consensus and practical algorithm.
Vasiliki N et al. Lung Cancer. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
TTF-1 expression in lung adenocarcinoma: clinicopathologic, genomic, and immunophenotypic correlates and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.
Di Federico A et al. J Thorac Oncol. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer.
Liao J et al. Cancer Cell. 2026
SCLCAdvanced/Metastatic (IV)2026
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials.
Zhou DD et al. Lung Cancer. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis.
Wang Y et al. Lung Cancer. 2026
EGFR mutantAll Stages2026
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer.
Soo RA et al. Lung Cancer. 2026
GeneralAdvanced/Metastatic (IV)2026
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.
Socinski MA et al. JAMA Oncol. 2026
SCLCAll Stages2026
SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China.
Lu S et al. J Thorac Oncol. 2026
SCLCAll Stages2026
Tumor Inflammation-Associated Neurotoxicity Masquerading as Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report.
Torasawa M et al. J Thorac Oncol. 2026
ImmunotherapyAll Stages2026
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.
Senan S et al. J Thorac Oncol. 2026
SCLCAdvanced/Metastatic (IV)2026
First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial.
Fan Y et al. J Thorac Oncol. 2026
SCLCAll Stages2026
Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial.
Novello S et al. J Thorac Oncol. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.
Scherpereel A et al. J Clin Oncol. 2026
ImmunotherapyAll Stages2026
Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab.
Rousseau A et al. JAMA Oncol. 2026
ROS1 fusionAll Stages2026
Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study.
Li W et al. J Clin Oncol. 2026
ROS1 fusionAdvanced/Metastatic (IV)2026
Entrectinib in Asian patients with ROS1 fusion-positive non-small cell lung cancer: updated efficacy and safety analysis.
Lu S et al. Lung Cancer. 2026
ALK fusionAdvanced/Metastatic (IV)2026
Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.
Ahn BC et al. JAMA Oncol. 2026
RET fusionAll Stages2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry.
Marinello A et al. Clin Cancer Res. 2026
RET fusionAll Stages2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.
Waliany S et al. Clin Cancer Res. 2026
RET fusionAll Stages2026
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.
Wu YL et al. N Engl J Med. 2026
RET fusionAdvanced/Metastatic (IV)2026
RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy.
Sun Z et al. Lung Cancer. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.
Oberstein PE et al. J Clin Oncol. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response.
Prabhakaran S et al. Cancer Res. 2026
SCLCAll Stages2026
Combination of Lurbinectedin plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer Patients.
Ponce S et al. J Thorac Oncol. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
A multicenter prospective study of single nucleotide polymorphisms in the PDCD1 (programmed cell death 1) gene in patients with metastatic lung adenocarcinoma treated with pembrolizumab.
Chiari R et al. Lung Cancer. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.
Zhong H et al. Lancet Oncol. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis.
Alexander M et al. Lung Cancer. 2026
SCLCAll Stages2026
Brief Report: Low Delta-like Ligand 3 expression and T Cell Exhaustion Drive Resistance to Tarlatamab combined with anti-PD-1 in Small-Cell Lung Cancer.
Fukuda A et al. J Thorac Oncol. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.
Paz-Ares L et al. Lung Cancer. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung).
He K et al. ESMO Open. 2026
SCLCAdvanced/Metastatic (IV)2026
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
Zhou C et al. N Engl J Med. 2026
SCLCAdvanced/Metastatic (IV)2026
Thymic Composition Predicts Radiation Pneumonitis in Locally Advanced NSCLC.
Chaunzwa TL et al. J Thorac Oncol. 2026
SCLCAdvanced/Metastatic (IV)2026
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC.
Mouri A et al. Clin Cancer Res. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.
Levy B et al. J Thorac Oncol. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial.
Zalcman G et al. J Thorac Oncol. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study.
Reck M et al. J Thorac Oncol. 2026
GeneralEarly (I-III)2026
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.
Higgins KA et al. J Clin Oncol. 2026
ImmunotherapyAll Stages2026
Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung).
Cuppens K et al. Eur J Cancer. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.
Aldea M et al. Ann Oncol. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC.
Ross JS et al. J Thorac Oncol. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.
Hayashi H et al. J Thorac Oncol. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer.
Cho BC et al. Lung Cancer. 2026
SCLCAdvanced/Metastatic (IV)2026
Anlotinib + Toripalimab maintenance in Extensive-Stage small cell lung Cancer: Clinical efficacy and preclinical mechanism of anlotinib-induced neuroendocrine differentiation Suppression via Notch1.
Lv D et al. Lung Cancer. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
A Phase 2 Study of Stereotactic Ablative Radiotherapy Plus Atezolizumab Plus Tiragolumab in Treatment-naïve Patients with Advanced Non-small Cell Lung Cancer.
Lee JB et al. Clin Cancer Res. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.
Arriola E et al. Eur J Cancer. 2026
ImmunotherapyAll Stages2026
Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy.
Mankuzhy NP et al. J Thorac Oncol. 2026
KRAS G12CAll Stages2026
Emerging landscape of KRAS inhibitors in cancer treatment.
Riedl JM et al. Cancer Cell. 2026